FDA Halts New Obesity Drug Study After Patient Dies

Zafgen Inc said the U.S. Food and Drug Administration has put a partial hold on the development of its obesity treatment and confirmed that the 22-year-old patient who died during a late-stage study had been taking the drug.
Source: Diet and Fitness

Leave Comment

Your email address will not be published. Required fields are marked *